Solomon I. Hamburg

University of California, Los Angeles — United States

Medicine · Health Sciences

14h-index1.4kcitations28works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Myeloproliferative Neoplasms: Diagnosis and Treatment(6), Platelet Disorders and Treatments(4), Lymphoma Diagnosis and Treatment(3), Lung Cancer Treatments and Mutations(3), Hemoglobinopathies and Related Disorders(3)

Publications28 total

Complex Tricuspid and Pulmonic Carcinoid Heart Disease With Timely Surgical Repair
Texas Heart Institute Journal·2025Open Access
ELECTROPHYSIOLOGIC PROPERTIES OF HEART BLOCK INDUCED BY IMMUNE CHECKPOINT INHIBITOR MYOCARDITIS FROM CEMIPLIMAB
JACC CardioOncology·2022· 2 citedOpen Access
Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 – 100 × 109/L): Final Analysis of an Open-Label Phase 2 Study
Clinical Lymphoma Myeloma & Leukemia·2021· 16 citedOpen Access
Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study
Journal of Hematology & Oncology·2018· 23 citedOpen Access
Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma
Blood Cancer Journal·2014· 47 citedOpen Access
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts
Journal of Hematology & Oncology·2013· 94 citedOpen Access
A phase I dose-escalation study of TKM-080301, a RNAi therapeutic directed against polo-like kinase 1 (PLK1), in patients with advanced solid tumors: Expansion cohort evaluation of biopsy samples for evidence of pharmacodynamic effects of PLK1 inhibition.
Journal of Clinical Oncology·2013· 19 cited
Abstract LB-289: A phase I dose escalation study of TKM-080301, a RNAi therapeutic directed against PLK1, in patients with advanced solid tumors.
Cancer Research·2013· 31 cited
Results of a Phase 1 Dose-Escalation Study of Once-Weekly MLN9708, an Investigational Proteasome Inhibitor, in Patients with Relapsed/Refractory Lymphoma
Blood·2012· 8 cited
Efficacy, Hematologic Effects, and Dose of Ruxolitinib in Myelofibrosis Patients with Low Starting Platelet Counts (50–100 × 109/L): A Comparison to Patients with Normal or High Starting Platelet Counts
Blood·2012· 14 cited
Preliminary safety and efficacy of ruxolitinib in patients (pts) with primary and secondary myelofibrosis (MF) with platelet counts (PC) of 50–100x10<sup>9</sup>/L.
Journal of Clinical Oncology·2012· 11 cited
Laparoscopic Splenectomy for Hairy Cell Leukemia in Pregnancy
Case Reports in Medicine·2010· 21 citedOpen Access
Heart transplantation using bivalirudin as anticoagulant
Interactive Cardiovascular and Thoracic Surgery·2009· 14 citedOpen Access
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
The Lancet·2008· 851 cited
Long-Term Dosing of AMG 531 in Thrombocytopenic Patients with Immune Thrombocytopenic Purpura: 2-Year Update.
Blood·2007· 3 cited
Reduction in immunoglobulin (IVIG or anti D) use in patients with chronic immune thrombocytopenic purpura (ITP) receiving AMG 531
Blood·2007
Reduction in Immunoglobulin (IVIG or Anti D) Use in Patients with Chronic Immune Thrombocytopenic Purpura (ITP) Receiving AMG 531: Results from Two Phase 3 Randomized Placebo-Controlled Trials.
Blood·2007· 6 cited
Phase II trial of nolatrexed dihydrochloride [ThymitaqTM, AG 337] in patients with advanced hepatocellular carcinoma
Investigational New Drugs·2006· 17 cited
Phase II Multicenter Study of Induction Chemotherapy Followed by Concurrent Efaproxiral (RSR13) and Thoracic Radiotherapy for Patients With Locally Advanced Non–Small-Cell Lung Cancer
Journal of Clinical Oncology·2005· 28 citedOpen Access
Splenic Infarction Associated with Anti-Car diolipin Antibody: A Report of Two Cases
The American Surgeon·2004· 10 cited
page 1 of 2Next →

Frequent Co-authors

Moshe Talpaz(5), M. Rabinovitch(5), Roger M. Lyons(4), Troy H. Guthrie(4), Jeffrey S. Wasser(4), Howard R. Terebelo(4), Janet L. Nichol(4), Lawrence B. Afrin(4), Srđan Verstovšek(4), Vinod Pullarkat(3), Terry Gernsheimer(3), Adrian C. Newland(3), Josef T. Prchal(3), Katarzyna Jamieson(3), Gregory L. Ortega(3), Elliott F. Winton(3), Wei Peng(3), Susan Erickson‐Viitanen(3), Lance Leopold(3), Hagop M. Kantarjian(3)